SCI Pharmtech, Inc. (Taiwan, China)

SCI Pharmtech, Inc. was established in 1987, made public offering in 2002 and was listed in Taiwan Stock Exchange in 2004. The company is engaged in the research, development, manufacture and sale of bulk drugs and bulk drug intermediates. The company's bulk drugs include allopurinol, probucol, amobarbital, thiopental, pentobarbital sodium, sodium valproate, divalproate sodium, propafenone and marbofloxacin, among others. Its bulk drug intermediates include diethyl dipropylmalonate, propiophenone, dibenzosuberone, aminazole, diethyl ethyl (1-methylbutyl) malonate, diethyl isopropylmalonate and hydroxifenone, among others. In addition, the company provides specialty chemicals. During the year 2009, bulk drugs and bulk drug intermediates contributed approximately 48% and 40% of the company's total revenue, respectively. The company distributes its products within the domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.